SCHEMBL24023496

SCHEMBL24023496

OCCN1CCN(Cc2ccc(-c3ccccc3)cc2)CC1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHKA P35790 2/20 0.62
PKM P14618 1/20 0.62
NCOA3 Q9Y6Q9 1/20 0.60
SIGMAR1 Q99720 2/20 0.57
ALDH1A1 P00352 2/20 0.56
TSHR P16473 1/20 0.56
CYP2D6 P10635 2/20 0.56
CYP2C19 P33261 1/20 0.56
FAAH O00519 1/20 0.55
MC4R P32245 1/20 0.53
KCNH2 Q12809 1/20 0.52
HRH3 Q9Y5N1 2/20 0.52
HRH4 Q9H3N8 1/20 0.52
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
CCR3 P51677 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3037947 0.89 SIGMAR1 (0.72) PKMSIGMAR1ALDH1A1TSHRMC4R
SCHEMBL11347486 0.89 SIGMAR1 (0.72) PKMSIGMAR1ALDH1A1TSHRMC4R
SCHEMBL8070876 0.86 LSS (0.63) CHKAPKMSIGMAR1ALDH1A1HRH3
SCHEMBL16226080 0.85 SIGMAR1 (0.78) CHKASIGMAR1ALDH1A1TSHRCYP2D6
SCHEMBL8070873 0.84 PKM (0.56) PKMSIGMAR1ALDH1A1LMNA
SCHEMBL3687427 0.82 CHKA (0.87) CHKASIGMAR1ALDH1A1TSHRCYP2D6
SCHEMBL3979002 0.80 SIGMAR1 (0.63) PKMSIGMAR1ALDH1A1LMNA
SCHEMBL1690956 0.80 CYP2D6 (0.85) CHKASIGMAR1ALDH1A1TSHRCYP2D6
SCHEMBL10868742 0.79 MC4R (0.57) PKMSIGMAR1ALDH1A1TSHRMC4R
SCHEMBL16122104 0.79 ALDH1A1 (0.65) PKMALDH1A1TSHRHRH3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353642-A1 COMPOUNDS FOR TREATING MYELIN RELATED DISORDERS CASE WESTERN RESERVE UNIVERSITY 2021-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353642-A1 COMPOUNDS FOR TREATING MYELIN RELATED DISORDERS PMP22, MAG, MYT1 CHKA 536/4885PKM 3489/4885NCOA3 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.